Desmoda oral solution is now FDA-approved for central diabetes insipidus, allowing clinicians to tailor dosing to individual water balance patterns.

The oral solution is supplied in a 120mL bottle containing 25mg of sitagliptin per mL. Brynovin ™, an oral solution formulation of sitagliptin, is now available from Azurity Pharmaceuticals. Brynovin ...

Brivaracetam 10mg/mL; raspberry flavored. The precise mechanism by which Briviact exerts its anticonvulsant activity is not known. Brivaracetam displays a high and selective affinity for synaptic ...

The FDA has approved an oral liquid therapy for the treatment of central diabetes insipidus in people of all ages, according to a press release. Desmopressin acetate (Desmoda, Eton Pharmaceuticals) is ...

DEER PARK, Ill., May 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing ...

DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved IMKELDI (imatinib) oral solution, the first ...

Liquid alternative to desmopressin tablets allows for more precise dosing ...

FDA authorized desmopressin acetate oral solution (Desmoda) for CDI/AVP-D across all ages, representing the first FDA-approved oral liquid desmopressin formulation in the United States.